Mylan in 2017 was ordered to pay Vermont about $1 million as part of a $465 million national settlement to resolve claims under Vermont’s False Claims Act.
"On Sept. 27, the Securities and Exchange Commission announced that Mylan had agreed to pay $30 million to settle charges that it overcharged Medicaid by hundreds of millions of dollars for its EpiPen, its most profitable product. The EpiPen is a device that patients can use to inject themselves with medication when they are experiencing a severe allergic reaction. The $30 million is in addition to the earlier settlement. Mylan was criticized by lawmakers, health care advocates, and patients in 2016 after it increased the price of a two-pack of the anaphylaxis drug -- its signature product, the EpiPen - from $100 to over $600, with only one other competitive product on the market."
Read More at: